Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study

Table 1 Baseline characteristics

Characteristic	LAM group			History control group
	No.	CHB	LC	No.	CHB	LC
	(n = 238)	(n = 187)	(n = 51)	(n = 238)	(n = 190)	(n = 48)
Age (mean ± SD)	35.9 ± 11.7	33.3 ± 10.3	45.5 ± 11.6	34.7 ± 11.5	32.3 ± 9.9	44.4 ± 12.0
Sex, n (%)	197 (74.3)	149 (70.6)	48 (88.9)	197 (74.3)	153 (72.2)	44 (83)
Base HBeAg-positive, n (%)	153 (57.7)	134 (63.5)	19 (35.2)	157 (59.2)	139 (65.6)	18 (34)
Base ALT (U/mL)	150	157	124	212	221	173
Base HBV-DNA (copy/mL)	5.85E+7	7.3E+7	5.4E+6	3.6E+7	2.1E+7	8.4E+7
Follow-up time (yr)	5.1 (1.0-13.2)	5.0 (1.0-13.2)	5.2 (1.1-11.6)	3.8 (1.0-17.6)	3.9 (1.0-17.6)	3.1 (1.0-15.0)

LAM: Lamivudine; CHB: Chronic hepatitis B; LC: Liver cirrhosis.

Table 2 Risk factors of liver cancer

Factor	Assignment
Sex
Male	1
Female	0
Age	Age
Stop treatment
Stop	1
Never stop	0
Family history
No	0
Unknown	1
Yes	2
Baseline HBeAg
HBeAg-negative	1
HBeAg-positive	0
Viral breakthrough
Yes	1
No	0
Baseline DNA level (copy/mL)
< 104	0
104-99999	1
105-999999	2
≥ 106	3
Baseline ALT	ALT (IU/mL)
Diagnose
LC	1
CHB	0

ALT: Alanine transaminase; CHB: Chronic hepatitis B; LC: Liver cirrhosis; HBeAg: Hepatitis B e antigen.